Leqembi

News

Eisai, Biogen face delay to subcutaneous Leqembi

Eisai and Biogen are facing a delay in the FDA review of injectable Leqembi for initial dosing in Alzheimer's, viewed as a key growth driver.

News

Most patients "won't see benefit" with Alzheimer's drugs

A review of clinical data on amyloid-targeting Alzheimer's therapies has found absent or trivial efficacy, but is facing pushback from some experts.

News

Appeal finds NICE must reconsider Alzheimer's drugs

Lilly and Eisai's bid to secure NHS coverage of their Alzheimer's therapies has entered a new phase, after an appeal of last year's rejection by NICE.

News

Leqembi starts to deliver for Eisai and Biogen

Three years after its first launch in the US, there are signs that Biogen and Eisai's Alzheimer's Leqembi therapy is gathering sales momentum.

News

Eisai moves swiftly to expand subcutaneous Leqembi label

Before it has even launched, Eisai has filed to widen subcutaneous Leqembi's label to include starting as well as maintenance dosing in Alzheimer's.

News

Dose-at-home Leqembi for Alzheimer's cleared in US

Eisai and Biogen get FDA approval for subcutaneous Leqembi. Will it help stave off growing competition from Lilly's Kisunla in Alzheimer's treatment?

Eisai, Biogen face delay to subcutaneous Leqembi

Most patients "won't see benefit" with Alzheimer's drugs

Appeal finds NICE must reconsider Alzheimer's drugs

Leqembi starts to deliver for Eisai and Biogen

Eisai moves swiftly to expand subcutaneous Leqembi label

Dose-at-home Leqembi for Alzheimer's cleared in US

Doctors dismayed by report of NHS AI proposal

Discover a new era of healthcare panel engagement: Grounded ...

Leqembi

Editor's Picks